uniQure N.V. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
uniQure N.V. (QURE) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $500.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-02
- uniQure N.V. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $500.00K.
- uniQure N.V. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2016 was $17.00M, a 8.97% increase from fiscal 2015.
- uniQure N.V. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2015 was $15.60M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $500.00K 10-K · filed 2026-03-02 |
| 2016-12-31 | $17.00M 10-K · filed 2017-03-15 |
| 2015-12-31 | $15.60M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |